170 related articles for article (PubMed ID: 17513613)
1. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.
Hannay JA; Liu J; Zhu QS; Bolshakov SV; Li L; Pisters PW; Lazar AJ; Yu D; Pollock RE; Lev D
Mol Cancer Ther; 2007 May; 6(5):1650-60. PubMed ID: 17513613
[TBL] [Abstract][Full Text] [Related]
2. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.
Liu J; Zhan M; Hannay JA; Das P; Bolshakov SV; Kotilingam D; Yu D; Lazar AF; Pollock RE; Lev D
Mol Cancer Res; 2006 Nov; 4(11):803-10. PubMed ID: 17077165
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation.
Zhan M; Yu D; Liu J; Glazer RI; Hannay J; Pollock RE
J Biol Chem; 2005 Feb; 280(6):4825-33. PubMed ID: 15563462
[TBL] [Abstract][Full Text] [Related]
4. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression.
Zhan M; Yu D; Lang A; Li L; Pollock RE
Cancer; 2001 Sep; 92(6):1556-66. PubMed ID: 11745235
[TBL] [Abstract][Full Text] [Related]
5. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair.
Boichuk S; Bikinieva F; Nurgatina I; Dunaev P; Valeeva E; Aukhadieva A; Sabirov A; Galembikova A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266502
[TBL] [Abstract][Full Text] [Related]
7. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha.
Zhu QS; Ren W; Korchin B; Lahat G; Dicker A; Lu Y; Mills G; Pollock RE; Lev D
Cancer Res; 2008 Apr; 68(8):2895-903. PubMed ID: 18413758
[TBL] [Abstract][Full Text] [Related]
8. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene.
Arias-Lopez C; Lazaro-Trueba I; Kerr P; Lord CJ; Dexter T; Iravani M; Ashworth A; Silva A
EMBO Rep; 2006 Feb; 7(2):219-24. PubMed ID: 16322760
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
Zhang L; Hannay JA; Liu J; Das P; Zhan M; Nguyen T; Hicklin DJ; Yu D; Pollock RE; Lev D
Cancer Res; 2006 Sep; 66(17):8770-8. PubMed ID: 16951193
[TBL] [Abstract][Full Text] [Related]
10. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
11. Identification of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53.
Marreiros A; Czolij R; Yardley G; Crossley M; Jackson P
Gene; 2003 Jan; 302(1-2):155-64. PubMed ID: 12527206
[TBL] [Abstract][Full Text] [Related]
12. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
13. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein.
Hur J; Bell DW; Dean KL; Coser KR; Hilario PC; Okimoto RA; Tobey EM; Smith SL; Isselbacher KJ; Shioda T
Cancer Res; 2006 Oct; 66(20):10153-61. PubMed ID: 17047080
[TBL] [Abstract][Full Text] [Related]
14. LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.
Lin M; Xu M; Xu Z; Weng Z; Lin B; Lan Y; Liu Q; Lin X; Pan J
Hum Cell; 2021 Jul; 34(4):1163-1173. PubMed ID: 33822325
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids.
Brodowicz T; Wiltschke C; Kandioler-Eckersberger D; Grunt TW; Rudas M; Schneider SM; Hejna M; Budinsky A; Zielinski CC
Br J Cancer; 1999 Jul; 80(9):1350-8. PubMed ID: 10424735
[TBL] [Abstract][Full Text] [Related]
16. E2F1-regulated long non-coding RNA RAD51-AS1 promotes cell cycle progression, inhibits apoptosis and predicts poor prognosis in epithelial ovarian cancer.
Zhang X; Liu G; Qiu J; Zhang N; Ding J; Hua K
Sci Rep; 2017 Jun; 7(1):4469. PubMed ID: 28667302
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells.
Fong V; Osterbur M; Capella C; Kim YE; Hine C; Gorbunova V; Seluanov A; Dewhurst S
PLoS One; 2011; 6(12):e28714. PubMed ID: 22174876
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
Ren W; Korchin B; Zhu QS; Wei C; Dicker A; Heymach J; Lazar A; Pollock RE; Lev D
Clin Cancer Res; 2008 May; 14(9):2785-95. PubMed ID: 18451246
[TBL] [Abstract][Full Text] [Related]
19. Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.
Boven E; Pinedo HM; van Hattum AH; Scheffer PG; Peters WH; Erkelens CA; Schlüper HM; Kuiper CM; van Ark-Otte J; Giaccone G
Br J Cancer; 1998 Dec; 78(12):1586-93. PubMed ID: 9862568
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
